- New system addresses the needs of the medical community; builds on proven
efficacy and safety of TRELSTAR(R) -
CORONA, Calif., April 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has approved MIXJECT(TM), the new delivery system for TRELSTAR(R) (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer. MIXJECT(TM), developed and manufactured by Medimop Medical Projects Ltd. a subsidiary of West Pharmaceutical Services, Inc., combines the proven efficacy of TRELSTAR(R) DEPOT 3.75 mg and TRELSTAR(R) LA 11.25 mg with new features that make preparation, administration and disposal easier.
These new features include: a smaller 21-gauge needle for improved patient comfort; reconstitution without the use of a needle; and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA (Occupational Safety and Health Administration) regulations within the medical community.
"At Watson, we understand what matters most for the physicians who
prescribe our products and for the patients whose lives are impacted by
them. Through these types of innovations, we are committed to developing
effective, safe and convenient treatments that improve the lives of
patients with urological conditions," said Edward Heimers, Jr., Executive
Vice President and President of Watson's Brand Division. "The new
MIXJECT(TM) drug delivery system was designed with a smaller needle size
and updated features that promote OSHA compliance based on the needs and
suggestions from our customers in c
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved